



Press Release
April 16, 2014
Gothenburg, Sweden

Conference call interim report

Invitation to attend Vitrolife's conference call regarding presentation of the interim report for the period January - March 2014. The presentation will be held in English.

Time: Wednesday, April 23, 2014 at 10.00 a.m. CET.

Registration can preferably be done in advance under the following link:

<https://eventreg1.conferencing.com/webportal3/reg.html?Acc=800440&Conf=190307>

or shortly before time of the conference starts on:

Sweden dial in number: +46 (0)8 5052 01 10

UK dial in number: +44 (0)20 7162 0077

Conference name: Vitrolife, conference ID: 944026

Vitrolife participants:

Thomas Axelsson, CEO

Mikael Engblom, CFO

The press release for Vitrolife's interim report will be released at 8.30 CET on the same day.

Before the conference call, slides will be available at the company web page,

<http://www.vitrolife.com/en/Corporate/>

A recorded version of the presentation will be available for seven days on number +46 (0)8 5052 0333 (Sweden) or 020 7031 4064 (UK), access code 944026.

Gothenburg, April 16, 2014

VITROLIFE AB (publ)

Contact:

Mikael Engblom, CFO, phone +46 (0)31 721 80 14

Vitrolife is an international medical device Group. The Fertility product area develops, produces and markets medical devices for assisted reproduction. Work is also carried out to enable the use and handling of stem cells for therapeutic purposes.

Vitrolife has approximately 240 employees and the company's products are sold in about 110 markets. The company is headquartered in Gothenburg, Sweden, and there are also offices in USA, Australia, France, Italy, United Kingdom, China, Japan, Hungary and Denmark. The Vitrolife share is listed on NASDAQ OMX Stockholm, Small Cap.

Vitrolife AB (publ), Box 9080, SE-400 92 Göteborg, Sweden. Corporate identity number 556354-3452. Tel: +46 31 721 80 00.
Fax: +46 31 721 80 99. E-mail: info@vitrolife.com. Website: www.vitrolife.com.

Vitrolife is required to publish the information in this press release in accordance with the Swedish Securities Market Act and/or the Financial Instruments Trading Act. The information was submitted for publication on April 16, 2014 at 08:30 a.m.

This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.